Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Total Non-Current Liabilities (2016 - 2025)

Perspective Therapeutics' Total Non-Current Liabilities history spans 15 years, with the latest figure at $52.3 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 16.57% year-over-year to $52.3 million; the TTM value through Sep 2025 reached $52.3 million, down 16.57%, while the annual FY2024 figure was $50.4 million, 121.81% up from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $52.3 million at Perspective Therapeutics, up from $44.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $62.6 million in Q3 2024 and bottomed at $2.2 million in Q4 2021.
  • The 5-year median for Total Non-Current Liabilities is $9.9 million (2023), against an average of $20.8 million.
  • The largest annual shift saw Total Non-Current Liabilities soared 713.47% in 2023 before it decreased 16.57% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $2.2 million in 2021, then rose by 24.81% to $2.8 million in 2022, then skyrocketed by 713.47% to $22.7 million in 2023, then soared by 121.81% to $50.4 million in 2024, then rose by 3.75% to $52.3 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Total Non-Current Liabilities are $52.3 million (Q3 2025), $44.7 million (Q2 2025), and $44.6 million (Q1 2025).